Literature DB >> 6094457

Single-dose cefotaxime in the treatment of urinary tract infections in children: a randomized clinical trial.

H A Repetto, G J MacLoughlin.   

Abstract

Thirty-seven patients with a median age of 5 years with symptomatic lower or upper urinary tract infection, documented by a clean-catch midstream urine culture and sediment examination, completed a randomized study comparing the effectiveness of a single dose of cefotaxime with 10-day treatment with an antibiotic chosen by in-vitro sensitivities. Eighteen patients were randomly assigned to the cefotaxime group (50 mg/kg/im route) and 19 patients were placed in the 10-day therapy group. In the cefotaxime group 4/18 patients had an upper urinary tract infection and 11/18 had a history of recurrences. The causal organisms were Escherichia coli (16 cases) and Klebsiella pneumoniae (two cases). All patients had sterile urine 48 hours after therapy, and 2/18 cases had recurred 28 days later. In the 10-day treatment group, 7/19 patients had an upper urinary tract infection, 6/19 had a history of recurrences, 17 cases were caused by E. coli, one case by Citrobacter freundii and one case by K. pneumoniae. Eighteen of 19 patients had sterile urine 48 hours after therapy and 1 case remained symptomatic with positive culture. The other 18 patients had no recurrences. Rates of cures and recurrence in the compared groups were not statistically different (P greater than 0.05).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094457     DOI: 10.1093/jac/14.suppl_b.307

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Single dose trimethoprim for urinary tract infection.

Authors:  T Nolan; L Lubitz; F Oberklaid
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

Review 3.  Cefotaxime optimal dosage in adult patients. A reappraisal.

Authors:  A Simon; C A d'Aubrac; C Safran; C Carbon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.